Cencora, Inc.

NYSE: COR·Conshohocken, Pennsylvania·

Price
$356.94
Base IV
$268.23

Valuation snapshot

Above base case

At $356.94, the price sits between our base case ($268.23) and bull case ($481.71).

Values per share, from an .

No growth
…
Loading earnings power
Base case
$268.23
75% of the price · range $129.77–$481.71
Price vs base case
33% above
$356.94 against $268.23
Base casevalued by DCF
Price vs base
Priceclose 11‑16

Whisker on the base case runs bear $129.77 to bull $481.71. Values per share.

Price against each value

Bear case
$129.77
Price 175% above
No growth
…
—
Base case
$268.23
Price 33% above
Researched bygemini-3.8-flash-medium
Valuation Nov 5, 2026 · Price as of Nov 16, 2026How we got here

What does Cencora do?

Cencora distributes pharmaceuticals, over-the-counter products, and medical supplies to healthcare providers and manufacturers while providing supply chain, logistics, and data analytics services.

It brought in $332.8B of sales in the 12 months to Jun 2026.

Led by Robert P. Mauch, President and Chief Executive Officer since 2024. Cencora, Inc. Form 10-K for the Fiscal Year Ended September 30, 2024

Pharmaceutical order fulfillment in a distribution centerImage: Cencora
Industry
Industrials
Based in
Conshohocken, Pennsylvania
Trades on
NYSE as COR

Here is where each dollar a customer pays ends up. Out of every $1 of sales in the 12 months to Jun 2026, about 1¢ was left as profit after every cost, interest and tax. The biggest cost is making what it sells, 96¢ of every dollar.

  • Making what it sells96¢
  • Sales, marketing and admin2¢
  • Everything else it takes to operate1¢
  • Left as profit1¢
Totals of the four quarters to Jun 2026, from the company's own filings. The split by product is from the latest fiscal year.

Who pays Cencora, and for what?

Cencora distributes prescription and over-the-counter medicines, healthcare supplies, and animal health products to providers in the U.S. and other markets. It also earns revenue from logistics, consulting, data, and other services that help healthcare providers and drugmakers move and manage products.

Its customers include hospitals, pharmacies, clinics, doctors, veterinarians, and pharmaceutical and biotechnology manufacturers.

  • U.S. Human Health

    89%

    Distribution of medicines and healthcare products, plus related services for providers and manufacturers.

    Pharmaceutical order fulfillment in a distribution centerImage: Cencora
  • Animal Health

    2%

    Products and services for companion-animal and production-animal customers.

    MWI Animal Health online ordering interfaceImage: MWI Animal Health
  • Alliance Healthcare

    8%

    International pharmaceutical distribution, mainly in Europe.

  • Other International Healthcare Solutions

    2%

    International healthcare distribution and services, including specialty logistics and life-sciences consulting.

    World Courier temperature-controlled pharmaceutical shipping containerImage: World Courier
Share of the latest fiscal year's sales, as the company reports it.

Where its work physically happens, beyond headquarters:

  • Columbus National Distribution Center — Columbus, United States. Cencora's national distribution center gives pharmaceutical manufacturers a single shipping destination for its U.S. distribution network.
  • Dothan Specialty Distribution Center — Dothan, United States. One of Cencora's three U.S. facilities dedicated to specialty medicines, this center is being expanded to handle more temperature-sensitive products.
  • Harrison National Distribution Center — Harrison, United States. The planned 530,000-square-foot second national distribution center is intended to increase U.S. storage capacity and throughput.
  • Fontana Distribution Center — Fontana, United States. Cencora's planned 430,000-square-foot automated center is designed to nearly double the size of the West Coast facility it will replace.
  • Birmingham Central Logistics Centre — Birmingham, United Kingdom. The 300,000-square-foot automated center is designed to increase Alliance Healthcare's U.K. wholesale warehouse space by 25%.
See them on the globe

Cencora FY2025 Form 10-K

How is the business doing?

Sales grew from $189.9B in 2020 to $321.3B in 2025, about 11% a year.

Running the business leaves about 1¢ of each sales dollar as operating profit, up from 3¢ in 2020.

After paying for its upkeep and new investment, it had $4.1B of cash to spare in the 12 months to Jun 2026.

Sales$321.3B
20162025
Operating margin1%
20162025
Free cash flow$3.2B
20162025
Each bar is one fiscal year (2016–2025), summed from four published quarters; the latest is highlighted.

What does management say it's aiming for?

Cencora says it exists to help create healthier futures for people and animals.

“We are united in our responsibility to create healthier futures.”

About Cencora

Who is responsible for the plan?

Roles checked November 14, 2026.

What management says it is working on now:

Adjusted diluted earnings per share, Fiscal 2026
At least $17.90
Cencora to Acquire American Oncology Network to Strengthen Support of Community Oncology
Goals in management's own numbers. A target is a promise, not a result.

What's changing right now?

Growth is holding steady. In Q3 2026 it sold 5% more than a year earlier. The year before, quarters averaged 6%.

Its operating margin is about where it was a year ago, 1¢ per sales dollar.

Since Oct 2026 the share price has risen 8%, from $330.53 to $356.94.

Bull $481.71Base $268.23Bear $129.77Oct 30Nov 16 · $356.94
Daily closing prices we have recorded, set against our bear-to-bull range. Our price records start October 30, 2026.

Recently

Coming up

Our own estimate moved too: the base case went from $216.13 to $268.23 a share between our last two valuations.

What could go wrong?

No business is a sure thing. These are the risks we found, starting with the ones the company itself names. Where a risk would change part of the valuation, it says which.

  1. Dependence on a few large customers

    The ten largest customers represented about 66% of fiscal 2025 revenue, and Walgreens and Boots together accounted for about 25%. Losing a major customer or renewing its contract on less favorable terms could hurt revenue and cash flow.

    From the company's own filingsWould hit how fast sales growCencora FY2025 Form 10-K

  2. Competitive pressure

    Cencora competes with other distributors, manufacturers selling directly, pharmacy chains, and service providers. Price competition or industry consolidation could weaken its ability to retain customers or protect profits.

    From the company's own filingsWould hit how much of each sale it keepsCencora FY2025 Form 10-K

  3. Regulation of medicine distribution

    Rules on tracking, licensing, pricing, and drug shortages may require costly changes to systems, inventory, and operations. Failure to comply could lead to fines or interruptions to some activities.

    From the company's own filingsWould hit how much of each sale it keepsCencora FY2025 Form 10-K

  4. Cybersecurity and system disruptions

    The company relies on computer systems to manage inventory, orders, billing, and payments. A cyberattack or system outage at Cencora or a service provider could interrupt deliveries, expose sensitive data, or increase costs.

    From the company's own filingsWould hit how fast sales growCencora FY2025 Form 10-K

  5. Acquisition and integration challenges

    Cencora says acquired businesses may fail to meet expectations or take more time and money to integrate than planned. The company also announced a proposed acquisition of American Oncology Network that still requires regulatory and shareholder approvals.

    From the company's own filingsWould hit how fast sales growCencora FY2025 Form 10-K

  6. Drug pricing and policy changes

    Changes to manufacturer prices, government pricing policies, or direct-to-consumer drug sales could alter how Cencora is paid for distribution services and affect its revenue or profits.

    From the company's own filingsWould hit how much of each sale it keepsCencora FY2025 Form 10-K

  7. Annual revenue grew at faster rates of 9.31% in FY2025 and 12.12% in FY2024, indicating potential for higher baseline momentum

    From our researchWould hit how fast sales growCencora FY2025 Form 10-K

Is it a good business?

From 2016 to 2025 it earned between 21% and 87% on the capital invested in it, a median of 41%. Its cost of capital in the latest valuation is 7.4%; returns were above it in every one of the 9 years.

From 2016 to 2025 it earned between 18% and 689% on its shareholders' equity, a median of 85%.

Over 10 years its operating margin ranged from 3¢ to 1¢ per sales dollar, a median of 1¢. Gross margin ran from 3¢ to 4¢.

derived computed from the filingsassumption cost of capital from the latest valuation
Return on invested capital42%
20162025

Cost of capital 7.4%

Return on equity103%
20162025
Return on invested capital is operating profit after tax (at the median effective rate, 24%) over debt plus equity less cash at each fiscal year end. Return on equity is net income over equity. Both are computed from published quarters.

The number of shares has held roughly steady over the past year.

It owes $8.9B more than it holds in cash, about 2.9 years of operating profit.

What might it be worth?

The Valuation snapshot at the top of this page shows the answer. This is how we got there. A share is a slice of the business, so what a share is worth depends on what the business can earn for its owners from here on. We estimate that three ways, from cautious to hopeful, and call the result .

Today a share costs $356.94. Our put its value between $129.77 and $481.71, with $268.23 in the middle. Underneath sit two simpler checks: what it would cost to rebuild the business, its , and what today's profit is worth with no growth at all, its .

Bear case, $129.77

In this cautious scenario, drug pricing pressures and slowing sales growth cause profits to soften while higher technology and warehouse costs absorb more cash.

Base case, $268.23

In this steady baseline scenario, revenue grows at a healthy mid-single-digit pace supported by aging demographics and specialty medicines, while profits hold steady near recent levels.

Bull case, $481.71

In this optimistic scenario, booming demand for advanced specialty drugs and high-value medical practice services powers faster sales growth and expands profit margins.

Another way in: instead of asking what the business is worth, ask what today's price assumes it will do.

Why the gap?

The price expects more than we do.Price above value: 33%

For Cencora to be worth today's $356.94, sales would need to grow about 10.1% a year. We assume 4.4%. Over the last 5 years, sales grew 10.2% a year.

−2.5%0%+2.5%+5%+7.5%+10%+12.5%We assume 4.4%Price needs 10.1%Past 5 yrs 10.2%

Or, if sales grow 4.4% as we assume, the price works with a profit margin of 1.6% (we assume 1.3%).

Keep in mind: this is one way to read the price. Investors might be expecting other things, like higher profits or lower risk.

Do you think sales can grow 10.1% a year?

Try your own numbers

We're moderately sure of this range: it scores 65 out of 100 on our checks. The weakest point is terminal-value dependency.

Test the assumptions

Our base value of $268.23 rests on three assumptions. Change any of them to see how the value per share responds.

  • Revenue growth, 5-year average4.4%
  • Operating margin1.3%
  • Long-term growth rate2.8%

This is an educational explanation built from public filings and our own research, not investment advice. It does not tell you whether to buy or sell anything.

Base estimate

$268.23 -24.9%

Build